The company is currently building out its product portfolio to include additional cytokine profiling panels as well as tools for single-cell phosphoproteomics.
Bruker has postponed reporting of its final Q4 and full-year 2019 results, but reported preliminary Q4 revenues of $599.9 million and full-year revenues of $2.07 billion.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.
